Douglas “Doug” Langa was appointed Senior Vice President, Head of North America Operations and President of Novo Nordisk Inc. in March 2017 and was promoted to Executive Vice President, North America Operations and President of Novo Nordisk Inc. in August 2017. In this role, Doug has full business responsibility for Novo Nordisk’s largest sales region, comprised of the United States and Canada.
Prior to his current role, Doug served as Senior Vice President, Market Access, where he was responsible for securing formulary access with key payer customers for Novo Nordisk brands. The Market Access function at Novo Nordisk covers payer marketing, contract strategy, pricing, and account management for all promoted and in-line brands. Under Doug’s leadership, the Market Access account executive team has received numerous third-party recognitions for their performance allowing a broad number of patients with chronic diseases to benefit from having access to Novo Nordisk brands.
Doug previously served as Corporate Vice President, Market Access. He joined Novo Nordisk in 2011 as the Senior Director, Managed Markets, in which he was responsible for strategy development and execution across Novo Nordisk’s diabetes portfolio.
Doug joined Novo Nordisk from GlaxoSmithKline (GSK), where he was the Senior Director of Payer Marketing. Prior to GSK, he spent the majority of his career at Johnson and Johnson, where he held various roles of increasing responsibility within Managed Markets, Sales Leadership, and Marketing. He has over 25 years of experience in the pharmaceutical and medical device industry.
Doug graduated from Widener University, earned his MBA from Fordham University, and holds professional certificates from The Wharton School and Harvard Business School.